Lucid Diagnostics’ Earnings Call: Momentum Amid Cash Strain

Lucid Diagnostics Inc. ((LUCD)) has held its Q4 earnings call. Read on for the main highlights of the call.

Lucid Diagnostics’ latest earnings call balanced clear commercial traction with equally clear financial strain. Executives highlighted accelerating test adoption, growing validation from major payers and the U.S. Department of Veterans Affairs, and strong real‑world clinical data, but acknowledged that cash burn, limited collections, and dependence on Medicare coverage still constrain the path to scale.

Strong Test Volumes Signal Growing Commercial Momentum

EsoGuard test volume reached 3,664 in Q4, beating management’s 2,500–3,000 target range and marking roughly 29% growth versus the prior quarter. Management suggested this level could reflect a new, higher run rate, driven by better field productivity and more focused targeting of high‑yield providers and sites.

Revenue Growth Lags Behind Billable Value

The quarter generated about $9 million in billable value, yet only $1.5 million—around 17%—could be recognized as revenue under accounting rules. Even so, recognized revenue grew about 24% versus the comparable period, underscoring strong underlying demand but also highlighting the gap between tests performed and cash actually realized.

VA FSS Contract Opens a Large Federal Channel

Lucid secured a Federal Supply Schedule contract with the U.S. Department of Veterans Affairs for EsoGuard, with pricing matched to the company’s Medicare rate of $938. The deal grants access to roughly 170 VA medical centers and an enrolled base of about 9 million veterans, positioning the VA system as a potentially major growth engine once adoption ramps.

Real‑World Study Supports Clinical and Commercial Case

Management showcased data from what it called the largest real‑world esophageal precancer testing experience to date, involving around 12,000 HET BRICK patients. EsoCheck achieved a 95% technical success rate, with 95% of procedures completed in under two minutes and no reported safety issues, providing powerful support for both scalability and payer discussions.

Payer Progress and LBM Coverage Build Reimbursement Credibility

On the payer front, UnitedHealthcare incorporated EsoGuard as an appropriate indicator for endoscopy within its guidelines, and the company has initiated credentialing. Executives also pointed to constructive engagements with Cigna, Anthem and Blue Cross Blue Shield plans, and signaled an upcoming announcement of their first positive coverage policy from a large laboratory benefits manager.

Non‑GAAP Loss Per Share Shows Operating Leverage

Non‑GAAP net loss per share improved to $0.10 in Q4 and $0.43 for the full year, roughly half the prior‑year level according to management. This trend indicates emerging operating leverage, achieved despite continued investments to build out commercial capabilities and infrastructure ahead of broader reimbursement.

Cash Balance and Cost Discipline Underpin Near‑Term Strategy

Lucid ended the year with $34.7 million of cash and emphasized tight stewardship of resources. Management highlighted a strategy of reallocating and optimizing existing commercial headcount rather than expanding, aiming to preserve runway while staying ready to accelerate once reimbursement clarity arrives.

Revenue Recognition Constraints and Weak Collections

While billable value was about $9 million in Q4, only around $1.5 million was recognized, and executives said roughly 80% of billable amounts are not currently collected. They tied this to reimbursement uncertainty and accounting limits on variable consideration, which together depress near‑term cash flow despite growing clinical usage.

Medicare LCD Seen as Critical Catalyst

The company remains heavily reliant on the timing of a local coverage determination from MolDx and Medicare, which it estimates covers 40%–50% of its addressable population. Until a draft and then final LCD are issued, revenue recognition and collection remain constrained, making the Medicare decision a central inflection point for the business.

High Cash Burn Highlights Runway Risk

Average cash burn in 2025 is running at about $11.1 million per quarter, including interest expense, against the $34.7 million year‑end cash balance. Management acknowledged that without improved collections, this implies a limited runway, and reiterated a cautious stance on operating expenses until reimbursement visibility improves.

Rising Operating Expenses and Noncash Note Charges

Non‑GAAP operating expenses rose from $44.3 million to $48.7 million year over year, with the $4.4 million increase attributed mainly to added commercial staff and higher G&A costs. GAAP results were further pressured by noncash fair‑value adjustments on convertible notes, with charges of $2.4 million in the quarter and $7.7 million for the year.

Claims Adjudication Shows Reimbursement Friction

Of Q4 claims submitted, about 76% had been adjudicated by the time of the call, and roughly half of those received an allowable amount. The average allowable was just $16.23 per test, with many denials citing reasons like “not medically necessary,” “prior authorization required,” or “additional records,” underscoring the current reimbursement headwinds.

Complex Capital Structure Raises Dilution Concerns

Lucid reported roughly 177 million common shares outstanding when including unvested awards and the impact of Series B conversion, and total potential issuance could approach 190 million if certain blockers fall away. PAVmed remains a large shareholder with significant voting influence, a structure that some investors may view warily given dilution risk.

EHR Integration Deferred Until Economics Improve

The company has started basic electronic health record integration using lower‑cost solutions, but full Epic integration is being held back. Management plans to invest in comprehensive Epic connectivity only once test volumes and reimbursement are robust enough to justify the expense, meaning some ordering efficiencies remain unrealized for now.

Guidance Centers on Medicare Decision and Scaling Potential

Management’s outlook hinges on an expected Medicare coverage path, outlining a draft LCD, a mandatory 45‑day comment window, and a final LCD with a one‑year retroactive payment period. They reiterated the strong Q4 volume of 3,664 tests, billed ASP of $2,499 and rising Medicare mix—now about 16% of volume—alongside VA FSS access and solid clinical validation, while reminding investors of a roughly $11.1 million quarterly cash burn and limited runway without improved collections.

Lucid Diagnostics’ earnings call painted a company with a validated technology and growing clinical demand that is still waiting for its reimbursement model to catch up. For investors, the story is a classic high‑risk, high‑reward setup: strong momentum with major payers and the VA on one side, and cash burn, low realized reimbursements and heavy reliance on a future Medicare LCD on the other.